Vor Biopharma (VOR) Stock Jumps Over 30% After JPMorgan Upgrade: What December 2025’s Rally Really Means for Investors
Vor Biopharma Inc. (NASDAQ: VOR) has exploded back onto traders’ screens. On December 9, 2025, the small-cap biotech surged roughly 31%, closing around $10.95 versus $8.36 the prior session, on volume tens of millions of shares—far above its recent daily average. StockAnalysis+1 The move followed new bullish coverage from JPMorgan, fresh clinical data around Vor’s lead drug telitacicept, and a controversial stock-option repricing that could shape the company’s governance story for years. GuruFocus+2Investing.com+2 Below is a detailed, SEO-friendly breakdown of the latest news, forecasts, and analyses around VOR stock as of December 9, 2025. Key takeaways on Vor Biopharma (VOR)